#USA #London #Concept Medical #SIRONA Trial #MagicTouch PTA

Concept Medical Presents Key Findings from SIRONA Trial at Charing Cross Symposium 2026

On April 27, 2026, Concept Medical Inc. made a significant announcement at the Charing Cross (CX) Symposium regarding the ongoing advancements in drug-delivery technologies for vascular interventions. The company showcased preliminary three-year follow-up data from its SIRONA randomized trial. This trial assesses the effectiveness of sirolimus-coated balloons compared to traditional paclitaxel-coated balloons in treating femoropopliteal artery disease.

Trial Overview

The SIRONA trial has been pivotal in understanding the comparative advantages between these two types of interventions. In a field that has predominantly relied on paclitaxel-based therapies, the trial is vital for generating head-to-head evidence. The preliminary findings presented by Principal Investigator Prof. Ulf Teichgräber indicate promising outcomes for the sirolimus-coated MagicTouch PTA balloons.

Results Findings

The data revealed that MagicTouch PTA demonstrated a superior freedom from clinically driven target lesion revascularization (cdTLR) when compared to the paclitaxel-coated balloon group, showing a rate of 88.2% versus 80.2%. This marked reduction in intervention rates significantly emphasizes the potential durability of sirolimus-based therapies in long-term patient outcomes.

Additionally, the overall mortality was consistent across both treatment groups at an impressive rate of 92.6%, indicating a sound long-term safety profile. Notably, the incidence of major amputations was extremely low, with no significant differences observed between both groups.

Expert Commentary

Prof. Teichgräber shared his enthusiasm for the preliminary findings, highlighting the promising results in sustaining lower rates of cdTLR over extensive follow-up periods. He mentioned, “These findings add vital long-term randomized evidence to our field and indicate the potential future role of sirolimus-coated balloons in managing peripheral artery disease.”

Dr. Manish Doshi, Founder and Managing Director of Concept Medical, emphasized the importance of long-term clinical data in validating the effectiveness of their technologies. He noted, “SIRONA exemplifies our commitment to going beyond short-term outcomes. These findings reinforce the comparative evidence supporting sirolimus-coated balloon therapy.”

Conclusion

The preliminary results from the SIRONA trial, pending Clinical Events Committee adjudication, suggest significant advancements in the treatment of femoropopliteal artery disease using sirolimus-coated devices. As Concept Medical continues to expand its impact internationally, these findings not only serve to enhance the credibility of their technologies but also pave the way for future innovations in the field of vascular interventions.